Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?

Cost Effectiveness and Resource Allocation

Volumn 8, Issue , 2010, Pages

  Gordon, Louisa G ^a   Hirst, Nicholas G ^a   Young, Robert P ^b   Brown, Paul M ^c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; VARENICLINE;

ADULT; ARTICLE; CANCER RISK; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; COUNSELING; FEMALE; GENETIC SCREENING; HEALTH CARE COST; HUMAN; LUNG CANCER; MALE; NICOTINE REPLACEMENT THERAPY; QUALITY ADJUSTED LIFE YEAR; RELAPSE; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE;

EID: 77957374284     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-8-18     Document Type: Article

References (37)

1. Scollo MM, Winstanley MH, . (Eds) Tobacco in Australia: Facts and Issues. 2008, Melbourne: Cancer Counci Victoria, Third, (Eds).
2. World Health Organisation Regional Office for Europe Prevalence of daily smoking by country, adults aged 15 years and over, European Region. 2005, WHO, World Health Organisation Regional Office for Europe.
3. Warner KE, Mackay JL. Smoking cessation treatment in a public-health context. Lancet 2008, 371:1976-1978. 10.1016/S0140-6736(08)60846-6, 18555898.
4. Cromwell J, Bartosch WJ, Fiore MC, Baker T, Hasselblad V. Cost effectiveness of the AHCPR guidelines for smoking. Journal of the American Medical Association 1997, 278:1759-1766. 10.1001/jama.278.21.1759, 9388153.
5. Gordon LG, Graves N, Hawkes A, Eakin E. A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol. Chronic Illness 2007, 3:101-129. 10.1177/1742395307081732, 18083667.
6. Shearer J, Shanahan M. Cost effectiveness analysis of smoking cessation interventions. Aust N Z J Public Health 2006, 30:428-434. 10.1111/j.1467-842X.2006.tb00458.x, 17073223.
7. Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, Gardner HD, Sullivan R, Gamble GD. Lung cancer susceptibility model based on age, family history and genetic variants. PLoS ONE 2009, 4:e5302. 10.1371/journal.pone.0005302, 2668761, 19390575.
8. Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin JM. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 2002, 37:241-256. 10.1016/S0169-5002(02)00107-1, 12234692.
9. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:29S-55S. 10.1378/chest.07-1347, 17873159.
10. Bize R, Burnand B, Mueller Y, Rege Walther M, Cornuz J. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2009, 15:CD004705.
11. Cameron LD, Sherman KA, Marteau TM, Brown PM. Impact of genetic risk information and type of disease on perceived risk, anticipated affect, and expected consequences of genetic tests. Health Psychol 2009, 28:307-316. 10.1037/a0013947, 19450036.
12. McBride CM, Bepler G, Lipkus IM, Lyna P, Samsa G, Albright J, Datta S, Rimer BK. Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev 2002, 11:521-528.
13. Heitjan DF, Asch DA, Ray R, Rukstalis M, Patterson F, Lerman C. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J 2008, 8:391-399. 10.1038/sj.tpj.6500492, 18347612.
14. Welton NJ, Johnstone EC, David SP, Munafo MR. A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res 2008, 10:231-240. 10.1080/14622200701767761, 2257987, 18188764.
15. Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of abstinence: a meta-analysis. Addict Behav 2008, 33:1516-1520. 10.1016/j.addbeh.2008.05.012, 2577779, 18706769.
16. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. 2006, Oxford: Oxford University Press.
17. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008, 23:CD000146.
18. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 2008, 9:649-656. 10.1016/S1470-2045(08)70154-2, 2601691, 18556244.
19. Audrain J, Boyd NR, Roth J, Main D, Caporaso NF, Lerman C. Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial. Addict Behav 1997, 22:741-751. 10.1016/S0306-4603(97)00060-9, 9426791.
20. Carpenter MJ, Strange C, Jones Y, Dickson MR, Carter C, Moseley MA, Gilbert GE. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med 2007, 33:22-28. 10.1207/s15324796abm3301_3, 17291167.
21. Ito H, Matsuo K, Wakai K, Saito T, Kumimoto H, Okuma K, Tajima K, Hamajima N. An intervention study of smoking cessation with feedback on genetic cancer susceptibility in Japan. Prev Med 2006, 42:102-108. 10.1016/j.ypmed.2005.10.006, 16325899.
22. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008, 6:84. 10.1186/1477-7525-6-84, 2579282, 18939982.
23. Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001, 19:855-863. 10.2165/00019053-200119080-00007, 11596837.
24. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000, 18:3302-3317.
25. Cornuz J, Gilbert A, Pinget C, McDonald P, Slama K, Salto E, Paccaud F. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control 2006, 15:152-159. 10.1136/tc.2005.011551, 2564651, 16728744.
26. Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008, 24:51-61.
27. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). Pharmacoeconomics 2001, 19:1103-1109. 10.2165/00019053-200119110-00004, 11735677.
28. Jackson KC, Nahoopii R, Said Q, Dirani R, Brixner D. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J Occup Environ Med 2007, 49:453-460. 2, 10.1097/JOM.0b013e3180459ff2, 17426529.
29. Thavorn K, Chaiyakunapruk N. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control 2008, 17:177-182. 10.1136/tc.2007.022368, 18285385.
30. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 2006, 15:280-285. 10.1136/tc.2005.015487, 2563611, 16885576.
31. Hoogenveen RT, van Baal PH, Boshuizen HC, Feenstra TL. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation. Cost Eff Resour Alloc 2008, 6:1. 10.1186/1478-7547-6-1, 2267164, 18190684.
32. Australian Institute of Health and Welfare (AIHW) ACIM (Australian Cancer Incidence and Mortality) Books. 2009, Canberra: Australian Institute of Health and Welfare, Australian Institute of Health and Welfare (AIHW).
33. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2005. 2008, Bethesda: National Cancer Institute.
34. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. Jama 2003, 289:313-322. 10.1001/jama.289.3.313, 12525232.
35. Department of Health & Ageing National Hospital Cost Data Collection, Cost weights for AR-DRG v.5.1 (Round 11, 2006-07). 2008, Canberra: Commonwealth of Australia, Department of Health & Ageing.
36. Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer 2005, 48:171-185. 10.1016/j.lungcan.2004.11.001, 15829317.
37. Hurley SF, Matthews JP. The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff Resour Alloc 2007, 5:2. 10.1186/1478-7547-5-2, 1796848, 17241477.